Molecular Devices Acquires Cellesce Ltd
December 6, 2022
Molecular Devices, a life-science instrumentation company, has acquired Cellesce Ltd, a Cardiff-based developer and manufacturer of patient-derived organoids (PDOs) for large-scale drug screening. The deal expands Molecular Devices' 3D biology capabilities and combines Cellesce's industrial-scale PDO production with Molecular Devices' automated organoid screening platforms to accelerate adoption of physiologically relevant cell models in drug discovery.
- Buyers
- Molecular Devices, LLC
- Targets
- Cellesce Ltd
- Industry
- Biotechnology
- Location
- Wales, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
OrganaBio Acquires Excellos Operating Assets, Creating a Bicoastal Cell Therapy CTDMO
May 13, 2026
Healthcare Services
OrganaBio acquired substantially all of the operating assets of San Diego-based Excellos Inc. to establish a bicoastal cell therapy contract testing, development and manufacturing organization (CTDMO). The deal retains the core Excellos team and creates Excellos Labs, an OrganaBio subsidiary, expanding redundancy and geographic coverage for cell therapy services including PBMC isolation and cryopreservation.
-
ARCHIMED Acquires Majority Stake in Cellese
April 9, 2024
Consumer Products
Global healthcare private equity firm ARCHIMED has acquired a majority stake in Cellese, the Irvine, California–based developer of growth factor- and exosome-based dermo-cosmetic products sold under the AnteAGE brand. ARCHIMED will support Cellese's commercialization and international expansion while founder Ian Sanderson and his family roll a meaningful portion of proceeds into a minority stake.
-
Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
July 11, 2023
Biotechnology
Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
-
Bio-Rad Acquires Celsee, Inc.
April 9, 2020
Biotechnology
Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.
-
ICON plc Acquires MolecularMD Corporation
February 21, 2019
Healthcare Services
ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.